HLA Class I Supertypes: A Revised and Updated Classification by Sidney, John et al.
 
HLA Class I Supertypes: A Revised and Updated Classification
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Sidney, John, Bjoern Peters, Nicole Frahm, Christian Brander, and
Alessandro Sette. 2008. HLA class I supertypes: a revised and
updated classification. BMC Immunology 9: 1.
Published Version doi://10.1186/1471-2172-9-1
Accessed February 19, 2015 7:45:23 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:5333510
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAABioMed  Central
Page 1 of 15
(page number not for citation purposes)
BMC Immunology
Open Access Research article
HLA class I supertypes: a revised and updated classification
John Sidney1, Bjoern Peters1, Nicole Frahm2, Christian Brander2 and 
Alessandro Sette*1
Address: 1Division of Vaccine Discovery, The La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA and 
2Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, 149 13 Street, Charlestown, MA 02129, USA
Email: John Sidney - jsidney@liai.org; Bjoern Peters - bpeters@liai.org; Nicole Frahm - nfrahm@partners.org; 
Christian Brander - brander@helix.mgh.harvard.edu; Alessandro Sette* - alex@liai.org
* Corresponding author    
Abstract
Background: Class I major histocompatibility complex (MHC) molecules bind, and present to T
cells, short peptides derived from intracellular processing of proteins. The peptide repertoire of a
specific molecule is to a large extent determined by the molecular structure accommodating so-
called main anchor positions of the presented peptide. These receptors are extremely
polymorphic, and much of the polymorphism influences the peptide-binding repertoire. However,
despite this polymorphism, class I molecules can be clustered into sets of molecules that bind
largely overlapping peptide repertoires. Almost a decade ago we introduced this concept of
clustering human leukocyte antigen (HLA) alleles and defined nine different groups, denominated
as supertypes, on the basis of their main anchor specificity. The utility of this original supertype
classification, as well several other subsequent arrangements derived by others, has been
demonstrated in a large number of epitope identification studies.
Results:  Following our original approach, in the present report we provide an updated
classification of HLA-A and -B class I alleles into supertypes. The present analysis incorporates the
large amount of class I MHC binding data and sequence information that has become available in
the last decade. As a result, over 80% of the 945 different HLA-A and -B alleles examined to date
can be assigned to one of the original nine supertypes. A few alleles are expected to be associated
with repertoires that overlap multiple supertypes. Interestingly, the current analysis did not identify
any additional supertype specificities.
Conclusion: As a result of this updated analysis, HLA supertype associations have been defined
for over 750 different HLA-A and -B alleles. This information is expected to facilitate epitope
identification and vaccine design studies, as well as investigations into disease association and
correlates of immunity. In addition, the approach utilized has been made more transparent,
allowing others to utilize the classification approach going forward.
Background
Class I major histocompatibility complex (MHC) mole-
cules bind short peptides derived from the processing of
proteins, and present them on the cell surface for T cell
scrutiny. Functional MHC molecules are made of a heavy
(α) chain and a β2-microglobulin chain. Peptide binding
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by class I molecules is accomplished by interaction of the
peptide amino acid side chains with discrete pockets
within the peptide-binding groove of the MHC molecule
formed by the α1 and α2 domains of the heavy chain.
Typically, in the case of human leukocyte antigen (HLA)
class I, the main binding energy is provided by the inter-
action of residues in position 2 and the C-terminus of the
peptide with the B and F binding pockets of the MHC
molecule, respectively [1-8], although side chains
throughout the ligand can have a positive or negative
influence on binding capacity. The common chemical
specificity of the peptide side chains amongst ligands
bound by a specific MHC molecule is termed the binding
motif [9].
MHC molecules are extremely polymorphic, and over a
thousand allelic variants have already been described at
the class I A and B loci. Most of the polymorphism is
located in the peptide-binding region, and as a result each
variant is believed to bind a unique repertoire of peptide
ligands. Despite this polymorphism, HLA class I mole-
cules can be clustered into groups, designated as super-
types, representing sets of molecules that share largely
overlapping peptide binding specificity. Each supertype
can be described by a supermotif that reflects the broad
main anchor motif recognized by molecules within the
corresponding supertype. For example, molecules of the
A2-supertype share specificity for peptides with aliphatic
hydrophobic residues in position 2 and at the C-terminus,
while A3-supertype molecules recognize peptides with
small or aliphatic residues in position 2 and basic residues
at the C-terminus.
The first supertypes were described in the mid-1990's by
our group [10]. Using motifs derived from binding data or
the sequencing of endogenously bound ligands, along
with simple structural analyses, nine different supertypes
were defined [11,12]. Initial peptide binding studies
allowed the identification of several peptides with degen-
erate binding capacity for the A2- [13-15], A3- [16-18] and
B7-supertypes [19,20]. In subsequent years, additional
binding data have been published to confirm the B44-
[21], A1- and A24-supertypes [22].
Over time, a number of different and more sophisticated
computational approaches have been implemented by
others to classify HLA class I alleles into clusters or super-
types [23-32]. While in general agreement, additional
supertypes, representing either sub-clusters of the original
nine or completely novel groupings, have been proposed
[23,32]. Despite differences in various classification
schemes, the concept of HLA supertypes has been effec-
tively used to characterize and identify promiscuously rec-
ognized T cell epitopes from a variety of different disease
targets, including measles-mumps-rubella [33], SARS
[34], EBV [35,36], HIV [37-41], Kaposi' Sarcoma Associ-
ated Human Herpesvirus [42,43], HCV [16,44], HBV
[45,46], HPV [47], influenza [48], P. falciparum [49-52],
LCMV [53], Lassa virus [54], F. tularensis [55], vaccinia
[56-58], and also cancer antigens [59-68]. Supertypes
have also been utilized as a component in several
approaches and algorithms designed for predicting pep-
tide candidates with degenerate HLA class I binding
capacity [69-77]. Finally, supertypes have also been exam-
ined as a variable in studies of disease association, rates of
susceptibility, and outcome [37,78-86].
The original classification proposed by Sette and Sidney
[12] comprised about 100 different class I MHC alleles.
However, over the last 10 years, substantially more bind-
ing data has been generated, and through the efforts of
several seminal MHC-related databases, including SYF-
PEITHI [87], HLA Ligand [88], FIMM [89] and MHCBN
[90], MHC binding motif information is readily accessi-
ble. Up-to-date compilations of MHC sequence data are
also readily available in the IMGT database [91]. Herein,
we analyze the complete list of alleles available through
IMGT (release 2.9) using a simple approach largely based
on compilation of published motifs, binding data, and
analyses of shared repertoires of binding peptides, in con-
junction with clustering based on the primary sequence of
the B and F peptide binding pockets. As a result, we now
provide updated supertype assignments, with new assign-
ments for about 700 different HLA-A and -B alleles. This
will permit the use of our original classification scheme
based on current data and its comparison to alternative
supertype classification methodologies developed since
then.
Results
MHC sequences and peptide binding pockets
α1 and 2 chain residues comprising the B and F peptide-
binding pockets of 945 HLA A and B class I molecules
were extracted and aligned. Based on crystallographic
studies [1,4,6,8], residues 7, 9, 24, 34, 45, 63, 66, 67, 70,
and 99 were considered as comprising the B pocket, which
engages the peptide residue in position 2. The residues
comprising the F pocket, which engages the peptide C-ter-
minal residue, were defined as 74, 77, 80, 81, 84, 95, 97,
114, 116, 123, 133, 143, 146, and 147. Further, for the B
pocket we defined the subset of residues 9, 45, 63, 66, 67,
70, and 99 as key residues. In the F pocket, the key resi-
dues are those in positions 77, 80, 81 and 116.
Pocket chemical specificity
Next, we defined the broad chemical specificity associated
with the different B and F pockets. Table 1 summarizes the
amino acid residues generally associated with each partic-
ular description of binding specificity. The particular set of
residues associated with each use of a descriptor may varyBMC Immunology 2008, 9:1 http://www.biomedcentral.com/1471-2172/9/1
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with context. While these descriptions largely follow clas-
sical textbook definitions, they also consider our own his-
torical use and experience with peptide binding studies.
For example, in our analyses we often consider the polar
residue Q along with more classically defined aliphatic
residues based on observed behavior in MHC peptide
binding studies [15,92,93]. It is also important to note
that some residues are assigned to multiple categories, as
their chemical specificity is compatible with different
emphases. For example, L would be considered as both
aliphatic and hydrophobic. The chemical specificities
defining each supertype are listed in Table 2.
Peptide-binding motif-based supertype assignments
As a starting point, we have largely utilized the nine super-
type designations derived previously [11,12], with a few
exceptions. These exceptions entail specificities that
appear to be compatible with multiple supertypes. More
specifically, we recognize that some alleles have reper-
toires overlapping both the A01 and A03 supertypes (e.g.,
A*3001; see Hamdahl et al., IEDB submission 1000945
[94-96]), and others with the A01- and A24-supertypes
(e.g., A*2902 [22]). Also, because it utilizes a non-canon-
ical main anchor spacing, and as a result appears to have
a repertoire that overlaps with other specificities, we have
presently separated HLA B*0801 and other alleles sharing
sequence and serological antigen similarities, as a separate
cluster. While these B*08 alleles utilize a unique mode of
peptide binding, it is likely that in most cases their reper-
toires overlap significantly with other supertypes, espe-
cially the B07-supertype (Sidney, Frahm, Brander and
Sette, unpublished observations). As a result, we have not
defined this a separate supertype.
Next, the available peptide-binding motifs were com-
piled. In total, 88 different class I motifs were identified.
Motif information was derived from our own peptide-
binding studies, or from the published scientific literature
as compiled in the SYFPEITHI database [87]. The basis for
each motif assignment is listed in Tables 3 and 4 for HLA-
A and -B alleles, respectively. Corresponding supertype
associations were assigned based on the criteria listed in
Table 2.
Pocket analysis and supertype assignments
The amino acids comprising the B and F peptide binding
pockets were compiled for all alleles for which complete
sequence information was available. The positions of spe-
cific MHC residues forming the corresponding pockets are
listed above. A reference panel of B and F pockets was gen-
erated to include all alleles for which the MHC-peptide
binding specificity has been defined (see Tables 3 and 4).
These B and F pocket structures, along with the associated
alleles and corresponding binding specificity are shown in
Tables 5 and 6, respectively.
Next, the B and F pocket structures of alleles whose pep-
tide binding specificity was unknown were compared
against the sequences in the reference panel. For each case,
an attempt was made to find an exact match with the full
set of residues in the corresponding pocket. If a match was
identified, the allele was assigned the associated specifi-
Table 1: Physiochemical functionality of peptide side chains.
Pocket specificity Associated amino acid residues
Acidic DE
Aliphatic LIVMQ
Aromatic FWY
Aromatic and aliphatic FWYLIVMQ
Aromatic and basic YRK
Aromatic and large hydrophobic FWYLIM
Basic RHK
Hydrophobic LIVMFWYA
Large hydrophobic FLIM
Proline P
Small AST
Small and aliphatic ATSVLIMQ
Small hydrophobic AV
Small, aliphatic and aromatic ASTVLIMQFWY
Table 2: HLA supertype specificity descriptions.
Supertype(s) B pocket specificity F pocket specificity
A01 Small and aliphatic Aromatic and large hydrophobic
A01 A03 Small and aliphatic Aromatic and basic
A01 A24 Small, aliphatic and aromatic Aromatic and large hydrophobic
A02 Small and aliphatic Aliphatic and small hydrophobic
A03 Small and aliphatic Basic
A24 Aromatic and aliphatic Aromatic, aliphatic and hydrophobic
B07 Proline Aromatic, aliphatic and hydrophobic
B08 Undefined Aromatic, aliphatic and hydrophobic
B27 Basic Aromatic, aliphatic, basic and hydrophobic
B44 Acidic Aromatic, aliphatic and hydrophobic
B58 Small Aromatic, aliphatic and hydrophobic
B62 Aliphatic Aromatic, aliphatic and hydrophobicBMC Immunology 2008, 9:1 http://www.biomedcentral.com/1471-2172/9/1
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city shown in Tables 5 and 6. If an exact match could not
be found, then a match with a key residue sequence was
attempted. If no match was identified, the allele was con-
sidered unassigned. For each allele where a match for the
full or, secondarily, key residue sequence could be identi-
fied for both the B and F pockets with any of the alleles
indicated in Tables 3 and 4, a corresponding HLA super-
type was assigned.
Of the 945 sequences analyzed, matches at both B and F
pockets were found for 764 (80.8%) (Table 7). Notably,
for the majority (57%) of alleles not in the reference panel
full sequence matches were identified at both the B and F
pockets. Figures 1 and 2 indicate the alleles associated
with each HLA-A or -B supertype, respectively. Conversely,
as an index, Additional file 1 provides the supertype
assignment for each of the 945 HLA-A and -B alleles exam-
ined, along with their respective B and F pocket structures.
At the HLA-A locus, alleles were fairly evenly distributed
amongst the four supertypes we have defined. Consider-
ing the alleles with broad, or dual, specificity (i.e., those
assigned as A01–A03 or A01–A24), the minimum was 57
Table 4: HLA-B motif/structure reference panel alleles.
Allele Basis for motif Supertype association
B*0702 Binding assay B07
B*0703 Pool sequencing/ligand elution B07
B*0705 Pool sequencing/ligand elution B07
B*0801 Binding assay B08
B*0802 Pool sequencing/ligand elution B08
B*1402 Pool sequencing/ligand elution B27
B*1501 Binding assay B62
B*1502 Pool sequencing/ligand elution B62
B*1503 Binding assay B27
B*1508 Pool sequencing/ligand elution B07
B*1509 Pool sequencing/ligand elution B27
B*1510 Pool sequencing/ligand elution B27
B*1512 Pool sequencing/ligand elution B62
B*1513 Pool sequencing/ligand elution B62
B*1516 Pool sequencing/ligand elution B58
B*1517 Pool sequencing/ligand elution B58
B*1518 Pool sequencing/ligand elution B27
B*1801 Binding assay B44
B*2702 Pool sequencing/ligand elution B27
B*2703 Pool sequencing/ligand elution B27
B*2704 Pool sequencing/ligand elution B27
B*2705 Binding assay B27
B*2706 Pool sequencing/ligand elution B27
B*2707 Pool sequencing/ligand elution B27
B*2709 Pool sequencing/ligand elution B27
B*3501 Binding assay B07
B*3503 Pool sequencing/ligand elution B07
B*3701 Pool sequencing/ligand elution B44
B*3801 Pool sequencing/ligand elution B27
B*3901 Pool sequencing/ligand elution B27
B*3902 Pool sequencing/ligand elution B27
B*3909 Pool sequencing/ligand elution B27
B*4001 Binding assay B44
B*4002 Binding assay B44
B*4006 Pool sequencing/ligand elution B44
B*4201 Binding assay B07
B*4402 Binding assay B44
B*4403 Binding assay B44
B*4501 Binding assay B44
B*4601 Pool sequencing/ligand elution B62
B*4801 Pool sequencing/ligand elution B27
B*5101 Binding assay B07
B*5102 Pool sequencing/ligand elution B07
B*5103 Pool sequencing/ligand elution B07
B*5201 Pool sequencing/ligand elution B62
B*5301 Binding assay B07
B*5401 Binding assay B07
B*5501 Pool sequencing/ligand elution B07
B*5502 Pool sequencing/ligand elution B07
B*5601 Pool sequencing/ligand elution B07
B*5701 Binding assay B58
B*5702 Pool sequencing/ligand elution B58
B*5801 Binding assay B58
B*5802 Binding assay B58
B*6701 Pool sequencing/ligand elution B07
B*7301 Pool sequencing/ligand elution B27
B*7801 Pool sequencing/ligand elution B07
Table 3: HLA-A motif/structure reference panel alleles.
Allele Basis for motif Supertype association
A*0101 Binding assay A01
A*0201 Binding assay A02
A*0202 Binding assay A02
A*0203 Binding assay A02
A*0204 Pool sequencing/ligand elution A02
A*0205 Binding assay A02
A*0206 Binding assay A02
A*0207 Binding assay A02
A*0214 Pool sequencing/ligand elution A02
A*0217 Pool sequencing/ligand elution A02
A*0301 Binding assay A03
A*1101 Binding assay A03
A*2301 Binding assay A24
A*2402 Binding assay A24
A*2601 Binding assay A01
A*2602 Pool sequencing/ligand elution A01
A*2603 Pool sequencing/ligand elution A01
A*2902 Binding assay A01 A24
A*3001 Binding assay A01 A03
A*3002 Binding assay A01
A*3003 Pool sequencing/ligand elution A01
A*3004 Pool sequencing/ligand elution A01
A*3101 Binding assay A03
A*3201 Binding assay A01
A*3301 Binding assay A03
A*3303 Published motif A03
A*6601 Pool sequencing/ligand elution A03
A*6801 Binding assay A03
A*6802 Binding assay A02
A*6901 Pool sequencing/ligand elution A02
A*7401 Binding assay A03BMC Immunology 2008, 9:1 http://www.biomedcentral.com/1471-2172/9/1
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alleles for A24, and the maximum was 95 alleles for A03.
75 alleles were assigned to the A02 supertype, and 80 to
the A01 supertype. At the HLA-B locus, the B07-supertype
is the largest, with 165 members. 19 alleles were associ-
ated with the B08 pattern. As noted above, we hypothesize
that alleles in this cluster will likely cross-react with other
supertypes (especially B07), so we do not consider this
group as a distinct supertype. The B58 supertype was
assigned only 22 alleles, making it the smallest supertype.
Novel supertypes could not be identified, but several 
alleles have specificities spanning two different supertypes
From Tables 5 and 6, it is evident that not all possible
combinations of B and F pocket specificities are present
within the reference panel. For example, there are no alle-
les associated with a preference for acidic residues in posi-
tion 2 and basic residues at the C-terminus. Hence, we
were interested to see if combinations not found in the
original supertype assignments were revealed in the
present analysis. Interestingly, we did not identify any
new combinations. It is possible that new specificities will
be identified from amongst the set of 181 alleles for which
pocket matches could not be obtained. However, we also
note that in the majority of these cases, matches could be
made if one allowed a single conservative residue change
(e.g., E to D). Thus, based on the analyses done to date, it
would appear that the set of supertype specificities cur-
rently identified will cover virtually all HLA-A and -B class
I MHC alleles.
Table 5: B pocket structures of reference panel alleles.
Residues1 Key residues Reference panel allele(s) Associated supertype(s) Specificity
YDSVENIFNY DENIFNY B*0801-2 B08 Undefined
YFAVMEKVHC FMEKVHC A*0207 A02 Small and aliphatic
YFAVMEKVHF FMEKVHF A*0217 A02 Small and aliphatic
YFAVMEKVHY FMEKVHY A*0201-4 A02 Small and aliphatic
YFAVMENMHY FMENMHY A*0101 A01 Small and aliphatic
YFAVMENVHY FMENVHY A*3201, A*7401 A01 A03 Small and aliphatic
YFAVMENVQY FMENVQY A*0301 A03 Small and aliphatic
YHSVTEISNS HTEISNS B*3701 B44 Acidic
YHSVTNISNY HTNISNY B*1801 B44 Acidic
YHTVEEICKY HEEICKY B*2702-7, B*2709 B27 Basic
YHTVENICKY HENICKY B*7301 B27 Basic
YHTVKEISNY HKEISNY B*4001-2, B*4006, B*4501 B44 Acidic
YSAVMEKVHF SMEKVHF A*2301, A*2402 A24 Aromatic and aliphatic
YSAVMENVHY SMENVHY A*3002-4 A01 Small and aliphatic
YSAVMENVQY SMENVQY A*3001 A01 A03 Small and aliphatic
YTAVMENVHY TMENVHY A*3101 A03 Small and aliphatic
YTAVMNNVHY TMNNVHY A*3301, A*3303 A03 Small and aliphatic
YTAVMQNVQY TMQNVQY A*2902 A01 A24 Small, aliphatic and aromatic
YYAVENIYQY YENIYQY B*5501-2, B*5601 B07 Proline
YYAVGNIYQY YGNIYQY B*5401 B07 Proline
YYAVMEISNY YMEISNY B*1501, B*1512 B62 Aliphatic
YYAVMEKVHY YMEKVHY A*0205, A*0206, A*0214 A02 Small and aliphatic
YYAVMEKYQY YMEKYQY B*4601 B62 Aliphatic
YYAVMENMSY YMENMSY B*1516-17, B*5701-2 B58 Small
YYAVMENVQY YMENVQY A*1101 A03 Small and aliphatic
YYAVMNIFNY YMNIFNY B*1508 B07 Proline
YYAVMNISNY YMNISNY B*1502, B*1513 B62 Aliphatic
YYAVMNNVHY YMNNVHY A*2601-3 A01 Small and aliphatic
YYAVMNNVQY YMNNVQY A*6601, A*6801-2, A*6901 A02 A03 Small and aliphatic
YYAVTEISNY YTEISNY B*5201 B62 Aliphatic
YYAVTENMSY YTENMSY B*5801-2 B58 Small
YYAVTNIFNY YTNIFNY B*3501, B*3503, B*5101-3, B*5301, B*7801 B07 Proline
YYSVEEISNY YEEISNY B*1503, B*3902, B*4801 B27 Basic
YYSVENICNS YENICNS B*3909 B27 Basic
YYSVENICNY YENICNY B*1402, B*1509-10, B*1518, B*3801, B*3901 B27 Basic
YYSVENIYNY YENIYNY B*0703 B07 Proline
YYSVENIYQY YENIYQY B*0702, B*0705, B*4201, B*6701 B07 Proline
YYTVKEISNY YKEISNY B*4402-3 B44 Acidic
1. Based on data presented in Saper et al, and Madden (see Methods), the MHC residues utilized as constituting the B pocket are: 7, 9, 24, 34, 45, 63, 66, 
67, 70, and 99. Key residues are those in positions 9, 45, 63, 66, 67, 70, and 99.BMC Immunology 2008, 9:1 http://www.biomedcentral.com/1471-2172/9/1
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Table 6: F pocket structures of reference panel alleles.
Residues1 Key residues2 Reference panel allele(s) Associated 
supertype(s)
Specificity
DDTLYIIEHYWTKW DTLH A*3001 A01 A03 Aromatic and basic
DDTLYIIRDYWTKW DTLD A*0301, A*1101 A03 Basic
DDTLYIMQDYWTKW DTLD A*3101, A*3301, A*3303, A*7401 A03 Basic
DDTLYIMRDYWTKW DTLD A*6801 A03 Basic
DDTLYIRHYYWTKW DTLY A*6802 A02 Aliphatic
DDTLYIRQDYWTKW DTLD A*6601 A03 Basic
DDTLYLNHDYWTKW DTLD B*2703, B*2705 B27 Hydrophobic and basic
DDTLYLNHHYWTKW DTLH B*2709 B27 Large hydrophobic
DDTLYLSNYYWTKW DTLY B*2707 B27 Large hydrophobic
DDTLYVRHYYWTKW DTLY A*6901 A02 Aliphatic
DGNLYWTNFYWTKW GNLF B*7301 B27 Large hydrophobic
DNIAYLMHYYWTKW NIAY A*2301, A*2402 A24 Large hydrophobic
DNIAYLNHDYWTKW NIAD B*2702 B27 Large hydrophobic
DNTAYLSNYYWTKW NTAY B*0802 B08 Hydrophobic
DNTLYIIEHYWTKW NTLH A*3002-4 A01 Aromatic
DNTLYIIRDYWTKW NTLD A*0101 A01 Aromatic
DNTLYIMRDYWTKW NTLD A*2902 A01 A24 Aromatic and large 
hydrophobic
DNTLYIRQDYWTKW NTLD A*2601 A01 Aromatic
DNTLYIRQNYWTKW NTLN A*2602 A01 Aromatic
DSIAYIMQDYWTKW SIAD A*3201 A01 Aromatic
DSNLYLRDSYWTKW SNLS B*4601 B62 Large hydrophobic
DSNLYLRNFYWTKW SNLF B*3901-2, B*3909, B*6701 B07 B27 Hydrophobic
DSNLYLSDYYWTKW SNLY B*0702-3 B07 Hydrophobic
DSNLYLSNYYWTKW SNLY B*0705, B*0801, B*4201 B07 Hydrophobic
DSNLYLWNFYWTKW SNLF B*1402 B27 Hydrophobic
DSNLYWTNLYWTKW SNLL B*5401, B*5501-2, B*5601 B07 Small hydrophobic
DSNLYWTNYYWTKW SNLY B*7801 B07 Hydrophobic
DSTLYLNDYYWTKW STLY B*2706 B27 Large hydrophobic
DSTLYLNHDYWTKW STLD B*2704 B27 Large hydrophobic
HDTLYIRQDYWTKW DTLD A*2603 A01 Aromatic
HDTLYLMHYYWTKW DTLY A*0217 A02 Aliphatic
HDTLYLRHYYWTKW DTLY A*0202, A*0205, A*0214 A02 Aliphatic
HDTLYVMHYYWTKW DTLY A*0204 A02 Aliphatic
HDTLYVRHYYWTKW DTLY A*0201, A*0203, A*0206-7 A02 Aliphatic
YDTLYIRNFYWTKW DTLF B*3701 B44 Hydrophobic
YNIAYIRDSYWTKW NIAS B*1513, B*5301, B*5801 B07 B58 B62 Large hydrophobic
YNIAYIVDSYWTKW NIAS B*5701 B58 Large hydrophobic
YNIAYIVNYYWTKW NIAY B*5702 B58 Large hydrophobic
YNIAYLRHDYWTKW NIAD B*1517 B58 Large hydrophobic
YNIAYLRNFYWTKW NIAF B*3801 B27 Large hydrophobic
YNIAYLWDSYWTKW NIAS B*5802 B58 Large hydrophobic
YNIAYWRDSYWTKW NIAS B*1516 B58 Large hydrophobic
YNIAYWTNYYWTKW NIAY B*5101-3, B*5201 B07 B62 Large hydrophobic
YNTAYIRDDYWTKW NTAD B*4402-3 B44 Hydrophobic
YSNLYIRDFYWTKW SNLF B*3503 B07 Hydrophobic
YSNLYIRDSYWTKW SNLS B*1502, B*3501 B07 B62 Hydrophobic
YSNLYLRDSYWTKW SNLS B*1501, B*1503, B*1508, B*1512, B*1518, B*1801 B07 B27 B44 B62 Large hydrophobic
YSNLYLRDYYWTKW SNLY B*1510 B27 Hydrophobic
YSNLYLRNYYWSKL SNLY B*4001 B44 Hydrophobic
YSNLYLRNYYWTKW SNLY B*1509 B27 Hydrophobic
YSNLYLSNYYWSKL SNLY B*4801 B27 Hydrophobic
YSNLYLSNYYWTKW SNLY B*4002 B44 Hydrophobic
YSNLYWRNLYWTKW SNLL B*4501 B44 Small hydrophobic
YSNLYWTNYYWTKW SNLY B*4006 B44 Hydrophobic
1. Based on data presented in Saper et al, and Madden (see Methods), the MHC residues utilized as constituting the F pocket are: 74, 77, 80, 81, 84, 95, 
97, 114, 116, 123, 133, 143, 146, and 147. Key residues are those in positions 77, 80, 81, and 116.
2. The key residue pockets DTLD, DTLH and DTLY are each associated with two different, although overlapping, specificity descriptions. In each case, 
one description is associated with HLA B27 alleles, and in the other with HLA A alleles. In assigning key residue matches, matches were assigned on the 
basis of corresponding locus.BMC Immunology 2008, 9:1 http://www.biomedcentral.com/1471-2172/9/1
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In addition to A*2902 and A*3001, the present analysis
has identified 17 alleles expected to have a specificity
overlapping two supertypes. Nine alleles matched pocket
preference patterns that would be compatible with both
the A01- and A03-supertypes, and another 10 with the
A01- and A24-supertypes. In the former case, the associa-
tion was established on the basis of pocket matches with
A*3001. Not surprisingly, several, but not all, of the alle-
les assigned the A01–A03 specificity also share the A30
antigen. The A01–A24 cross-reactivity pattern was estab-
lished on the basis of pocket matches with A*2902. All of
the alleles associated with the A01–A24 pattern also
shared the A29 antigen.
Unexpected supertype assignments
Typically, the supertype assignment for a particular allele
follows the predominant assignment for other alleles
sharing the same serological antigen. With this in mind,
we did identify several instances where the current classi-
fication differed from what was expected based on serol-
ogy or previous classification (Table 8). Of these, the more
striking ones involve alleles for which the assigned super-
type represents a non-conservative change in the binding
specificity from what would have been expected. For
example, A*0265 and A*0280, which are associated with
the A02 serological antigen, and thus might be expected to
have an F pocket specificity for hydrophobic/aliphatic res-
idues, were found to have an F pocket matching that of
A03 supertype alleles, which have a specificity for posi-
tively charged residues. Similarly, B*4012 and B*4440
were found to have B27 supertype B pockets, associated
with a preference for positively charged residues, when a
B44 supertype specificity for acidic residues might have
been expected.
As noted above, in the present analysis, and contrary to
what was done in the original analysis, we did not make
supertype assignments for alleles without an exact or key
match by considering conservative substitutions. As a
result of this more conservative approach, we now no
longer assign supertypes to some alleles previously given
a supertype designation (Table 9). In the majority of these
cases, however, the original designation would still seem
to be a reasonable assumption.
Discussion
In the present study we have attempted to classify almost
1000 HLA-A and -B class I alleles into supertypes. This is
nearly a 10-fold increase in the number of alleles com-
pared to our original classification done about a decade
ago [12]. Besides providing supertype assignments for
considerably more alleles, the present report has
attempted to make more transparent how the original
"phenomenological" classifications were done. About
80% of the 945 alleles examined were classified into one
of the nine supertypes identified previously. Analysis of B
and F pocket specificity patterns did not suggest the exist-
ence of any novel supertypes.
HLA supertypes do not necessarily demarcate groups of
alleles with completely non-overlapping repertoires. A
binding repertoire overlapping multiple supertypes has
been demonstrated previously, for example, in the cases
of A*2902 [22] and A*3001 (see Hamdahl et al., IEDB
submission 1000945 [94-96]). In the present study we
have identified 17 other alleles that would appear to have
specificities that bridge either the A01 and A03 super-
types, or the A01 and A24 supertypes. At the same time,
individual peptides can be readily identified that bear a
Table 7: Quantification of supertype assignments.
Classification criteria
Supertype (n) Binding assay Pool sequencing or 
ligand elution
Full sequence match 
at B and F
1 full and 1 key 
sequence match
Key residue match at 
B and F
A01 61 4 4 42 11 0
A01 A03 9 1 0 4 4 0
A01 A24 10 1 0 8 1 0
A02 75 7 4 57 7 0
A03 86 6 2 68 10 0
A24 47 2 0 36 9 0
B07 165 6 11 96 52 0
B08 19 1 1 13 4 0
B27 98 2 16 52 27 1
B44 108 6 2 57 43 0
B58 22 3 3 12 4 0
B62 64 1 5 44 12 2
Unassigned 181 - - - - -
Total 945 40 48 489 184 3BMC Immunology 2008, 9:1 http://www.biomedcentral.com/1471-2172/9/1
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particular supermotif, but that do not bind individual
HLA allele members of the supertype, or that bind alleles
of other supertypes, even supertypes associated with a dif-
ferent locus. Typically, in the first case, these phenomena
result from differences in motif compatibility, perhaps at
secondary positions. The second case likely reflects over-
lap(s) between the supertypes in terms of specificity,
although in rare cases binding can be accomplished when
no main anchor motif compatibility is apparent.
These observations are exemplified by a large scale analy-
sis of the capacity of a non-redundant set of 252 known
EBV and HIV derived epitopes to bind a panel of 30 differ-
ent HLA class I A and B molecules (Sidney, Frahm,
Brander and Sette, unpublished observations). It was
found that about 21% of the peptides bearing a specific
supermotif bound a given allele in the corresponding
supertype with an affinity of 100 nM, or better. By con-
trast, only in 1% of the cases considered did an allele bind
a peptide that did not have the corresponding supermotif.
At the same time, it was noted that in the set of peptides
utilized 62% (155/252) have motifs associated with 2 or
more supertypes. The pattern of binding also followed
this general promiscuity. It is also significant to note that
when the same library of peptides was examined for rec-
ognition in HIV/EBV patients, it was found that ~95% of
the epitopes were recognized in individuals not express-
ing the allele the epitope was originally reported to be
Supertype classification of HLA-A alleles Figure 1
Supertype classification of HLA-A alleles. The alleles associated with each HLA-A supertype, multiple supertypes, or that 
are unclassified, are shown. Under each supertype, alleles are group (by color) on the basis of the stringency of selection: 
experimentally established motif (i.e., reference panel) (green), exact match(es) in the B and F pockets (white), one exact and 
one key residue pocket match (yellow), key residue match(es) at B and F pockets (grey). Alleles with no match at one or both 
pockets are listed with red font.
HLA A-supertypes
A01
A*0101 A*0103 A*0112 A*2609 A*2618 A*3012 A*3602 A*2501 A*3603
A*2601 A*0104 A*0114 A*2610 A*2619 A*3202 A*3604 A*2502 A*7410
A*2602 A*0106 A*0115 A*2611 A*2621 A*3205 A*2504 A*8001
A*2603 A*0107 A*2604 A*2612 A*2623 A*3206 A*2622
A*3002 A*0108 A*2605 A*2613 A*2624 A*3207 A*3110
A*3003 A*0109 A*2606 A*2614 A*2626 A*3209 A*3203
A*3004 A*0110 A*2607 A*2615 A*3006 A*3210 A*3204
A*3201 A*0111 A*2608 A*2617 A*3009 A*3601 A*3208
A01 A03
A*3001 A*3008 A*3011 A*3014 A*3015 A*0252A * 3013 A*6806 A*6807
A01 A24
A*2902 A*2901 A*2905 A*2909 A*2911 A*2913
A*2903 A*2906 A*2910 A*2912
A02
A*0201 A*0209 A*0224 A*0240 A*0257 A*0271 A*6827 A*0241
A*0202 A*0211 A*0225 A*0243 A*0258 A*0272 A*6828 A*0242
A*0203 A*0212 A*0226 A*0244 A*0259 A*0274 A*0250
A*0204 A*0213 A*0227 A*0245 A*0261 A*0275 A*0260
A*0205 A*0215 A*0228 A*0246 A*0262 A*0277 A*0273
A*0206 A*0216 A*0230 A*0247 A*0263 A*0278 A*0284
A*0207 A*0218 A*0231 A*0248 A*0266 A*0279 A*6815
A*0214 A*0219 A*0236 A*0249 A*0267 A*0282
A*0217 A*0220 A*0237 A*0251 A*0268 A*0283
A*6802 A*0221 A*0238 A*0254 A*0269 A*0285
A*6901 A*0222 A*0239 A*0256 A*0270 A*0286
A03
A*0301 A*0302 A*0316 A*1112 A*3105 A*3404 A*6812 A*7402 A*0265
A*1101 A*0304 A*0317 A*1113 A*3106 A*3406 A*6813 A*7403 A*0280
A*3101 A*0305 A*1102 A*1114 A*3109 A*6602 A*6814 A*7404 A*0309
A*3301 A*0306 A*1103 A*1115 A*3111 A*6603 A*6816 A*7405 A*1106
A*3303 A*0307 A*1104 A*1116 A*3304 A*6604 A*6819 A*7407 A*1122
A*6601 A*0308 A*1105 A*1120 A*3305 A*6803 A*6821 A*7408 A*3112
A*6801 A*0310 A*1107 A*1121 A*3306 A*6804 A*6822 A*7409 A*6805
A*7401 A*0312 A*1108 A*1123 A*3307 A*6808 A*6824 A*7411 A*6820
A*0313 A*1109 A*3103 A*3402 A*6809 A*6825 A*6823
A*0314 A*1110 A*3104 A*3403 A*6810 A*6826 A*7406
A24
A*2301 A*2302 A*2310 A*2410 A*2422 A*2433 A*2440 A*2305 A*2442
A*2402 A*2303 A*2403 A*2411 A*2423 A*2434 A*2443 A*2312 A*2444
A*2304 A*2405 A*2413 A*2426 A*2435 A*2446 A*2417 A*2452
A*2306 A*2406 A*2418 A*2427 A*2437 A*2447 A*2425
A*2307 A*2408 A*2420 A*2428 A*2438 A*2448 A*2430
A*2308 A*2409 A*2421 A*2429 A*2439 A*2449 A*2441
Unclassified
A*0102 A*0233 A*0276 A*1118 A*2414 A*2432 A*2616 A*3007 A*3308
A*0113 A*0234 A*0281 A*1119 A*2415 A*2450 A*2620 A*3010 A*3401
A*0208 A*0235 A*0315 A*2309 A*2419 A*2451 A*2904 A*3102 A*3405
A*0210 A*0255 A*1111 A*2404 A*2424 A*2453 A*2907 A*3107 A*4301
A*0229 A*0264 A*1117 A*2407 A*2431 A*2503 A*2914 A*3108 A*6817BMC Immunology 2008, 9:1 http://www.biomedcentral.com/1471-2172/9/1
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Supertype classification of HLA-B alleles Figure 2
Supertype classification of HLA-B alleles. The alleles associated with each HLA-B supertype, multiple supertypes, or that 
are unclassified, are shown. Under each supertype, alleles are grouped (by color) on the basis of the stringency of selection as 
described in the legend to Figure 1.
HLA B-supertypes
B07
B*0702 B*0704 B*0741B * 3540B * 5109 B*5134 B*5510 B*0707 B*3518 B*5112 B*8102
B*0703 B*0706 B*0742B * 3541B * 5110 B*5135 B*5515 B*0709 B*3529 B*5113
B*0705 B*0715 B*0743 B*3542B * 5111 B*5136B * 5517 B*0712 B*3530B * 5114
B*1508 B*0719 B*3507 B*3543 B*5116 B*5138 B*5519 B*0714 B*3534 B*5120
B*3501 B*0720 B*3508 B*3544 B*5117 B*5302 B*5603 B*0716 B*3537 B*5137
B*3503 B*0721 B*3511 B*3545 B*5118 B*5306 B*5605 B*0717 B*3539 B*5304
B*4201 B*0722 B*3514 B*3546B * 5119 B*5308 B*5613 B*0718 B*3551B * 5508
B*5101 B*0724 B*3515 B*3554 B*5121 B*5310 B*5615 B*0723 B*3553 B*5511
B*5102 B*0725 B*3521 B*3555 B*5123 B*5403 B*5616 B*0736B * 3558B * 5513
B*5103 B*0726 B*3522 B*3557 B*5124 B*5404 B*7802 B*0737 B*3560 B*5514
B*5301 B*0730B * 3524 B*3561 B*5126 B*5406 B*7804 B*3502 B*3806 B*5602
B*5401 B*0731B * 3531B * 3910 B*5128 B*5407 B*3504 B*3807 B*5604
B*5501 B*0733 B*3532B * 3916 B*5129 B*5503 B*3505 B*3917 B*5609
B*5502 B*0734 B*3533 B*4204 B*5130B * 5504 B*3506 B*4206 B*5610
B*5601 B*0735 B*3535 B*4205 B*5131B * 5505 B*3509 B*4406 B*5611
B*6701 B*0739 B*3536B * 5105 B*5132B * 5507 B*3512 B*5104 B*5612
B*7801 B*0740B * 3538B * 5108 B*5133 B*5509 B*3517 B*5106 B*8101
B08
B*0801 B*0807 B*0811 B*0815 B*0819 B*0821 B*0823 B*0825 B*0803 B*0812
B*0802 B*0809 B*0813 B*0818 B*0820 B*0822 B*0824 B*0808 B*0816
B27
B*1402 B*1401 B*1593 B*3926 B*1405 B*3913 B*5518
B*1503 B*1403 B*1598B * 3927 B*1523 B*3915
B*1509 B*1406 B*1599 B*3929 B*1568 B*3924
B*1510 B*1407 B*2710 B*3930 B*2701 B*3928
B*1518 B*1537 B*2713 B*3932 B*2711 B*3933
B*2702 B*1547 B*2715 B*4012 B*2714 B*3934
B*2703 B*1549 B*2717 B*4802 B*2719 B*4440
B*2704 B*1551 B*2725 B*4803 B*2720 B*4807
B*2705 B*1552 B*2728 B*4804 B*2721 B*4808
B*2706 B*1554 B*3805 B*4805 B*2724
B*2707 B*1561 B*3809 B*4809 B*2727
B*2709 B*1562 B*3810 B*4810 B*2730
B*3801 B*1569 B*3811 B*4811 B*3526
B*3901 B*1572B * 3904 B*4812 B*3903
B*3902 B*1574 B*3907 B*4813 B*3905
B*3909 B*1580 B*3914 B*9503 B*3906
B*4801 B*1590B * 3918 B*3908
B*7301 B*1591B * 3923 B*3911
B44
B*1801 B*1553 B*1820 B*4029 B*4056B * 4422 B*4435 B*5001 B*1546B * 4028 B*4048B * 4420
B*3701 B*1803 B*3704 B*4035 B*4057 B*4424 B*4436 B*5002 B*1802 B*4030 B*4051 B*4425
B*4001 B*1805 B*4005 B*4039 B*4102 B*4426 B*4437 B*5004 B*1814 B*4033 B*4052B * 4431
B*4002 B*1806 B*4011 B*4040B * 4103 B*4427 B*4438B * 4003 B*4034 B*4058B * 4434
B*4006 B*1810 B*4014 B*4049 B*4404 B*4428 B*4503 B*4004 B*4036B * 4059 B*4439
B*4402 B*1811 B*4015 B*4050B * 4407 B*4429 B*4504 B*4009 B*4038B * 4101 B*4441
B*4403 B*1813 B*4016 B*4053 B*4413 B*4430 B*4505 B*4010 B*4042 B*4104 B*4442
B*4501 B*1815 B*4020 B*4054 B*4416 B*4432B * 4507 B*4018 B*4043 B*4106 B*4502
B*1819 B*4026 B*4055 B*4421 B*4433 B*4904 B*4019 B*4044 B*4107 B*4704
B*4023 B*4045 B*4405 B*4705
B*4024 B*4047 B*4414
B58
B*1516 B*1567 B*5804 B*5704
B*1517 B*1595 B*5806 B*5705
B*5701 B*5703 B*5807 B*5706
B*5702 B*5707 B*5808 B*5805
B*5801 B*5708 B*5809
B*5802 B*5709 B*5811
B62
B*1501 B*1505 B*1530 B*1548 B*1578 B*1596B * 5202 B*9502 B*1504 B*1558 B*1309
B*1502 B*1514 B*1531 B*1550 B*1581 B*1597 B*5203 B*9504 B*1507 B*1573 B*1313
B*1512 B*1515 B*1533 B*1560 B*1582 B*3528 B*5204 B*1524 B*1586
B*1513 B*1519 B*1534 B*1563 B*1583 B*4021 B*5205 B*1535 B*4408
B*4601 B*1520 B*1538 B*1565 B*1585 B*4603 B*5207 B*1542B * 4602
B*5201 B*1525 B*1539 B*1570 B*1588 B*4604 B*5208 B*1545
B*1528 B*1540 B*1575 B*1592B * 4605 B*7805 B*1555
Unclassified
B*0708 B*0806 B*1310 B*1543 B*1589 B*2723 B*3547 B*3709 B*4008 B*4410 B*4901 B*5402 B*8201
B*0710 B*0810 B*1311 B*1544 B*1804 B*2726 B*3548B * 3802 B*4013 B*4411 B*4902 B*5405 B*8202
B*0711 B*0814 B*1312 B*1556 B*1807 B*2729 B*3549 B*3803 B*4025 B*4412 B*4903 B*5512 B*8301
B*0713 B*0817 B*1404 B*1557 B*1808 B*3510 B*3550B * 3804 B*4027 B*4415 B*5107 B*5516 B*9501
B*0727 B*1301 B*1506 B*1564 B*1809 B*3513 B*3552 B*3808 B*4037 B*4417 B*5115 B*5606
B*0728 B*1302 B*1511 B*1566 B*1812 B*3516 B*3556 B*3912 B*4046 B*4418 B*5122 B*5607
B*0729 B*1303 B*1521 B*1571 B*1818 B*3519 B*3702 B*3919 B*4060 B*4506 B*5206 B*5608
B*0732 B*1304 B*1527 B*1576 B*2708 B*3520 B*3705 B*3920 B*4061 B*4701 B*5303 B*5614
B*0738 B*1306 B*1529 B*1577 B*2712 B*3523 B*3706 B*3922 B*4105 B*4702 B*5305 B*5901
B*0804 B*1307 B*1532 B*1584 B*2716 B*3525 B*3707 B*3931B * 4202 B*4703 B*5307 B*6702
B*0805 B*1308 B*1536 B*1587 B*2718 B*3527 B*3708 B*4007 B*4409 B*4806 B*5309 B*7803BMC Immunology 2008, 9:1 http://www.biomedcentral.com/1471-2172/9/1
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restricted by, and the promiscuity more often than not
involved an allele outside of the supertype associated with
originally described restricting allele [97]. Thus, it is
apparent that the lines of demarcation between super-
types can be fuzzy from the perspective of both the allelic
specificity and the peptide motif.
Restriction outside or across supertypes can also originate
from overlaps in supermotifs (e.g., A02 and B62), or for
alleles such as B*0801 which do not utilize the typical P2/
Cterminus anchor spacing. B*0801 utilizes P3 and P5, not
P2, and as such may be compatible with several super-
types and alleles. Thus, an A02- or A24-supertype epitope
cross-reacting with B*0801 is not an example of a motif
"failure", but merely reflects the fact that the specific pep-
tide has both motifs.
It is important to emphasize that supertypes are based on
MHC binding, and that MHC binding alone is not suffi-
cient criteria for T cell recognition. Indeed, hundreds of
examples of peptides that bind with remarkably high
affinity, but that are not recognized by T cells, have been
reported in the literature. We note that even in the best
affinity ranges (i.e., IC50 <10 nM), rarely more than 10%
of the peptides can be expected to be recognized [98].
Similarly, binding affinity is not necessarily correlative of
frequency of recognition [99]. It is true that the trend is
towards the most frequently recognized peptides being
also the highest affinity binders [38,50,100], but that is
not always the case, and there are clearly cases where the
dominant epitope has an IC50 of ~100 nM, while several
other non-recognized peptides have affinities in the <10
nM range.
It must also be emphasized that membership of an
epitope in a supertype is not sufficient to guarantee its rec-
ognition by T cells in the context of different MHC alleles.
Peptide binding to MHC is an absolute requirement for an
epitope to be recognized by T cells. At the same time,
many other factors, including protein expression and
processing, as well as T cell repertoire and the specific
Table 9: Alleles reclassified as "unassigned".
Allele Previous assignment B pocket match F pocket match Comments
A*0102 A01 - A01 full Single difference with A*0101 (F to S) at position 9 in B pocket is non-
conservative.
A*2404 A24 A24 full - F pocket key sequence is similar to A02 and B27 (hydrophobic), so 
A24 is still likely.
A*3401 A03 - A03 full N/K in 63/66 are relatively unique, otherwise similar to A03 in the B 
pocket.
A*4301 A01 - A01 full Q to N in 63 is only difference with A*2601, so A01 is still likely.
B*1301 B62 B62 key - Unusual F pocket.
B*1302 B62 B62 key - Unusual F pocket.
B*1506 B62 - B07 B27 B44 B62 full Single conservative change (Y to F) at position 99 of B pocket, 
comapred to B*1501; B62 still likely.
B*1521 B62 - B07 B62 full S to C change in position 67 is the onlyB pocket difference with 
B*1501, so B62 is still likely.
B*2708 B27 B27 full - Position 77 T to N change is only difference with b*2704, so B27 is still 
likely.
B*3802 B27 B27 full - I to T in position 80 of the F pocket is the only difference with B*3801, 
so B27 is still likely.
B*4701 B44 - B27 key Y to F at position 99 is the only difference with B*4402-3 in the B 
pocket, so B44 is still likely.
B*4901 B44 B44 full - F full pocket is similar to B*3801 (hydrophobic), so B44 is still likely.
Table 8: Unexpected and/or revised supertype assignments.
Supertype assignment
Allele Expected1or previous Current
A*0252 A02 A01 A03
A*0265 A02 A03
A*0280 A02 A03
A*3001 A24 A01 A03
A*3002 A24 A01
A*3003 A24 A01
A*3110 A03 A01
A*7410 A03 A01
B*3528 B07 B62
B*3806 B27 B07
B*3807 B27 B07
B*3910 B27 B07
B*3916 B27 B07
B*3917 B27 B07
B*4012 B44 B27
B*4021 B44 B62
B*4406 B44 B07
B*4408 B44 B62
B*4440 B44 B27
B*5518 B07 B27
1. Expected based on serological association.BMC Immunology 2008, 9:1 http://www.biomedcentral.com/1471-2172/9/1
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MHC context, come into play in determining whether a
peptide will be an epitope or not, or whether an epitope
will be promiscuously recognized within a specific super-
type. For example, Goulder and co-workers, studying B7-
supertype epitopes, found that differential selection pres-
sure exerted on HIV by CTL targeting identical epitopes,
but restricted by distinct HLA alleles from the same super-
type, can result in significant functional differences [101].
Macdonald et al., looking at two B44 subtypes described
as members of the HLA B44-supertype, reported that a
naturally selected dimorphism between the two mole-
cules alters class I structure, peptide repertoire, and T cell
recognition [102].
The intent of the current study was to derive an updated
classification of HLA class I MHC alleles on the basis of
primary anchor specificity. For the vast majority of HLA
class I molecules whose binding specificity have been
described by crystal structure, pool sequencing or peptide
binding studies, the main anchor interactions of the pep-
tide almost invariably involve the MHC B and F pockets,
while other pockets likely dictate secondary interactions.
This pattern also appears to be true for most macaque and
chimpanzee class I alleles studied to date.
There are exceptions, however, and indeed we have not
assigned B*08 alleles to a specific supertype in recogni-
tion of the fact that these alleles appear to utilize pockets
other than the B pocket as a primary anchor contact. For
HLA class I molecules in general, the B and F pockets are
the most likely main anchor contacts, while other pockets
likely dictate secondary interactions. High levels of cross-
reactivity have been experimentally demonstrated in the
case of 6 supertypes for alleles that vary at secondary pock-
ets [15,17,20-22].
By contrast, in the murine system it is well recognized that
other pockets are often the important primary peptide
contacts [103-109]. Thus, to utilize the classification
approach described here in the context of other species,
additional pockets may need to be considered. It is also
likely that the further parsing or sub-classifying of super-
types on the basis of secondary interactions can be accom-
plished.
In the case of HLA-B alleles, F pocket specificity is difficult
to correlate with a specific sequence, as a diverse pattern
of residues appears to be associated with similar binding
specificity. Independent of the residues in the F pocket,
most HLA-B alleles seem to bind hydrophobic residues.
Thus, assignment of B alleles was primarily driven by the
specificity exhibited by the B pocket. On the other hand,
it is also possible that greater resolution in the F pocket
could be achieved as more data become available to dis-
criminate different preference patterns. For example, in
the B7 supertype it is apparent that some alleles, like
B*3501, prefer large hydrophobic residues, such as Y.
Conversely, other B7 supertype alleles, such as B*5401,
seem to prefer small hydrophobic residues, such as A, at
the C-terminus. While we have noted these subtle differ-
ences in preference [20], in practice we have not found
that they significantly impact cross-reactivity between the
alleles. This perhaps suggests that the C-terminal anchor
in some contexts is less important, and that shared sec-
ondary preferences can have a stronger influence on
degenerate binding capacity than in other cases. At the
same time, it may be necessary to consider additional key
residues in the analysis of the F pocket. This is exemplified
in the cases of A*2603 and A*0301 which have the same
key F pocket residues, but which are associated with much
different specificity.
The vast majority of HLA-A and -B alleles fall into one of
the 9 supertypes we have described. There are likely rea-
sons for this [110], which include evolutionary relation-
ships, but also constraints and limitations inherent in the
epitope processing infrastructure. For example, no allele
has been identified to date that binds peptides with D, E,
Q or P at the C-terminus, which is in congruence with the
preferences of both proteasomal cleavage and TAP trans-
port [111], and an observation that has been applied in
the rational design of an in vitro test reagent tool (Pept-
Gen) offered as a tool by the Los Alamos HIV Sequence
Database [112].
Supertype classification should not be taken to necessarily
imply an evolutionary relationship. In some cases this is
largely true, as for example in the case of the A2-supertype,
where most alleles are associated with the A2 serological
antigen. In other cases the relationship is more compli-
cated, such as the gene conversion relationship between
the A2, A3 and A68 antigens. This latter example is some-
what of the exception that proves the rule. Supertype asso-
ciations are based on shared binding specificity, which
may result from both common ancestry and convergent
evolution [110]. Thus, while alleles within a supertype
may have a close evolutionary relationship, that is not a
given. Also, alleles (supertypes) sharing specificity at one
anchor position may be associated with very disparate
specificities at the other.
Other groups have also utilized various methodologies to
define supertypes. In general, our classification is in agree-
ment with those derived by other approaches, as com-
piled by Hertz [32], Lund [23] and Tong [31]. This is not
surprising given the good agreement observed between
our initial dataset and other classifications, and that the
methodology utilized here is not different from the one
utilized to derive the original assignments. If there are var-
iations, they usually represent the splitting of a supertype,BMC Immunology 2008, 9:1 http://www.biomedcentral.com/1471-2172/9/1
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or reassignment of individual alleles. As in any classifica-
tion problem of this kind, there is no absolute truth in
supertype assignments. The practical application of super-
type classification schemes to identify degenerately bind-
ing peptides will ultimately show what classification
scheme has the most practical value.
Conclusion
The present study represents an update to the HLA class I
supertype classification originally described almost a dec-
ade ago. Using MHC peptide binding motif data and
MHC sequence information that has since become availa-
ble, supertype associations have now been provided for
over 750 HLA-A and -B alleles. In addition, the approach
utilized has been made more transparent, allowing others
to utilize the classification approach going forward.
Methods
MHC sequences
The sequences of HLA A and B class I alleles were obtained
from the IMGT/HLA Database [91,113], release 2.9. Alle-
les with incomplete sequences were removed from further
analysis. The residues forming the B and F peptide bind-
ing pockets were aligned as described in the Results sec-
tion.
Peptide binding motif reference panel
The main anchor peptide binding motifs recognized by
HLA-A and -B molecules were compiled from our own
data, or as reported at the SYFPEITHI database [87]. The
HLA supertype associated with each motif was assigned as
defined previously [11,12], and/or on the basis of the
broad chemical specificity of each supertype indicated in
Tables 1 and 2.
Pocket analysis
The residues forming the B and F pockets of each allele in
the motif reference panel were compiled as a lookup table
in Microsoft Excel. Pockets were defined more stringently
by considering all residues forming the pocket, or less
stringently by considering only a subset of residues,
denominated as key residues, hypothesized to be most
directly involved in peptide binding. To assign a B and F
pocket specificity for each of the remaining alleles, the ref-
erence panel was scanned to identify exact pocket
sequence matches. If an exact match could be identified,
the allele was assigned the corresponding B or F pocket
specificity. Supertype assignments were then made by
matching the B and F pocket specificity pattern with the
supertype descriptions indicated in Table 2. If an exact
match for either the full pocket sequence or key residue
sequence could not be made at both the B and F pockets,
the allele was considered unassigned.
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